Patents by Inventor Hidekazu Toyofuku
Hidekazu Toyofuku has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240277702Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.Type: ApplicationFiled: December 15, 2023Publication date: August 22, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU
-
Publication number: 20240016937Abstract: The present invention provides a composition containing a nucleic acid molecule and a buffer, and having the features of (a) being in the form of a solution at ambient temperature; and (b) a content of the nucleic acid molecule after storage at 25° C., relative humidity 60% for 4 weeks, of not less than 80% relative to the content at the time of start of the storage.Type: ApplicationFiled: August 30, 2023Publication date: January 18, 2024Applicant: TORAY INDUSTRIES, INC.Inventors: Taimu YAMADA, Hidekazu TOYOFUKU
-
Publication number: 20230049327Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases.Type: ApplicationFiled: February 14, 2022Publication date: February 16, 2023Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi YAMASHITA, Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU, Tatsuya YAMAGUCHI, Masahiro SOTA, Shuuji KAWANO, Takayuki NAKAMURA, Ryohei ETO, Takuma IKEBUCHI, Kei MORIYAMA, Nobuaki ITO
-
Publication number: 20220305007Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.Type: ApplicationFiled: February 11, 2022Publication date: September 29, 2022Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU
-
Patent number: 11326163Abstract: Disclosed is a phosphorylation inhibitor of SMAD2/3 protein or a therapeutic agent for fibrosis which contains as an active ingredient, a nucleic acid that suppresses NEK6 (NIMA-related serine/threonine kinase 6) gene expression.Type: GrantFiled: July 30, 2018Date of Patent: May 10, 2022Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Kazuhisa Nakao, Junichi Ishiyama, Wataru Ichikawa, Atsushi Masui, Yunike Akasaka, Hidekazu Toyofuku, Aya Honda
-
Publication number: 20210115030Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases.Type: ApplicationFiled: August 4, 2020Publication date: April 22, 2021Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi YAMASHITA, Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU, Tatsuya YAMAGUCHI, Masahiro SOTA, Shuuji KAWANO, Takayuki NAKAMURA, Ryohei ETO, Takuma IKEBUCHI, Kei MORIYAMA, Nobuaki ITO
-
Publication number: 20210087556Abstract: Disclosed is a phosphorylation inhibitor of SMAD2/3 protein or a therapeutic agent for fibrosis which contains as an active ingredient, a nucleic acid that suppresses NEK6 (NIMA-related serine/threonine kinase 6) gene expression.Type: ApplicationFiled: July 30, 2018Publication date: March 25, 2021Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Kazuhisa Nakao, Junichi Ishiyama, Wataru Ichikawa, Atsushi Masui, Yunike Akasaka, Hidekazu Toyofuku, Aya Honda
-
Patent number: 10751426Abstract: The present invention provides a composition containing a single-stranded nucleic acid molecule consisting of a nucleotide sequence shown by 5?-AGCAGAGUACACACAGCAUAUACC-P-GGUAUAUGCUGUGUGUACUCUGCUUC-P-G-3? (SEQ ID NO: 1) (in the sequence, P is a proline derivative linker represented by (I) in the DESCRIPTION) and a buffer, and having the following features: (a) being in the form of a solution at ambient temperature; and (b) a content of the nucleic acid molecule after storage at 25° C., relative humidity 60% for 4 weeks, of not less than 80% relative to the content at the time of start of the storage.Type: GrantFiled: October 28, 2016Date of Patent: August 25, 2020Assignees: BONAC CORPORATIONInventors: Taimu Yamada, Hidekazu Toyofuku, Kohei Tahara, Risako Onodera, Hirofumi Takeuchi
-
Publication number: 20200163960Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.Type: ApplicationFiled: January 28, 2020Publication date: May 28, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU
-
Publication number: 20200140424Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl) butoxy]-1H-quinolin-2-one or of a salt thereof, and a process for producing the same.Type: ApplicationFiled: September 9, 2019Publication date: May 7, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi YAMASHITA, Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU, Tatsuya YAMAGUCHI, Masahiro SOTA, Shuuji KAWANO, Takayuki NAKAMURA, Ryohei ETO, Takuma IKEBUCHI, Kei MORIYAMA, Nobuaki ITO
-
Patent number: 10624889Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.Type: GrantFiled: September 12, 2017Date of Patent: April 21, 2020Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Tetsuya Sato, Takuya Minowa, Yusuke Hoshika, Hidekazu Toyofuku
-
Patent number: 10407415Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or of a salt thereof, and a process for producing the same.Type: GrantFiled: October 14, 2016Date of Patent: September 10, 2019Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Yamashita, Tetsuya Sato, Takuya Minowa, Yusuke Hoshika, Hidekazu Toyofuku, Tetsuya Yamaguchi, Masahiro Sota, Shuuji Kawano, Takayuki Nakamura, Ryohei Eto, Takuma Ikebuchi, Kei Moriyama, Nobuaki Ito
-
Patent number: 10337009Abstract: The invention provides a single-stranded nucleic acid molecule of (A) or (B) containing a TGF-?1 gene expression inhibitory sequence. The single-stranded nucleic acid molecule (A) consists of region (Xc), linker region (Lx) and region (X) from the 5?-side to the 3?-side, wherein linker region (Lx) has a non-nucleotide structure containing at least one of a pyrrolidine skeleton and a piperidine skeleton, and at least one of region (X) and region (Xc) contains the expression inhibitory sequence.Type: GrantFiled: December 15, 2015Date of Patent: July 2, 2019Assignee: BONAC CORPORATIONInventors: Takahiro Matsumoto, Hidekazu Toyofuku
-
Publication number: 20190010503Abstract: The present invention provides a single-stranded nucleic acid molecule inhibiting expression of a prorenin gene or a prorenin receptor gene, comprising only region (X), linker region (Lx) and region (Xc), wherein the aforementioned linker region (Lx) has a non-nucleotide structure comprising at least one of a pyrrolidine skeleton and a piperidine skeleton, and at least one of the aforementioned region (X) and the aforementioned region (Xc) comprises an expression inhibitory sequence comprising a nucleotide sequence consisting of at least 18 continuous nucleotides in any of an expression inhibitory sequence of a prorenin gene shown in SEQ ID NO: 1 to 5 and an expression inhibitory sequence of prorenin receptor gene shown in SEQ ID NO: 6 to 11.Type: ApplicationFiled: December 29, 2016Publication date: January 10, 2019Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, TOKYO MEDICAL UNIVERSITY, BONAC CORPORATIONInventors: Susumu ISHIDA, Atsuhiro KANDA, Masahiko KURODA, Hidekazu TOYOFUKU
-
Publication number: 20180339064Abstract: The present invention provides a composition containing a single-stranded nucleic acid molecule consisting of a nucleotide sequence shown by 5?-AGCAGAGUACACACAGCAUAUACC-P-GGUAUAUGCUGUGUGUACUCUGCUUC-P-G-3? (SEQ ID NO: 1) (in the sequence, P is a proline derivative linker represented by (I) in the DESCRIPTION) and a buffer, and having the following features: (a) being in the form of a solution at ambient temperature; and (b) a content of the nucleic acid molecule after storage at 25° C., relative humidity 60% for 4 weeks, of not less than 80% relative to the content at the time of start of the storage.Type: ApplicationFiled: October 28, 2016Publication date: November 29, 2018Applicants: BONAC CORPORATIONInventors: Taimu YAMADA, Hidekazu TOYOFUKU, Kohei TAHARA, Risako ONODERA, Hirofumi TAKEUCHI
-
Publication number: 20180099004Abstract: The present invention provides a single stranded nucleic acid molecule represented by the following formula (I): (I) (SEQ?ID?NO:?1) 5?-uagcaccauuugaaaucaguguucc-P- ggaacacugauuucaaauggugcuauu-3? wherein —P— shows a proline derivative linker represented by the following formula (Ia): an agent for treating corneal diseases such as ocular surface disorders and the like, comprising the single stranded nucleic acid molecule as an active ingredient.Type: ApplicationFiled: April 15, 2016Publication date: April 12, 2018Applicants: THE UNIVERSITY OF TOKYO, TOKYO MEDICAL UNIVERSITY, BONAC CORPORATIONInventors: Hirofumi TAKEUCHI, Tomohiko USUI, Masahiko KURODA, Masakatsu TAKANASHI, Shinichiro OHNO, Hidekazu TOYOFUKU, Kohei TAHARA, Risako ONODERA
-
Publication number: 20180092910Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.Type: ApplicationFiled: September 12, 2017Publication date: April 5, 2018Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU
-
Publication number: 20180036409Abstract: The present invention provides a composition containing a nucleic acid molecule and a buffer, and having the features of (a) being in the form of a solution at ambient temperature; and (b) a content of the nucleic acid molecule after storage at 25° C., relative humidity 60% for 4 weeks, of not less than 80% relative to the content at the time of start of the storage.Type: ApplicationFiled: October 30, 2015Publication date: February 8, 2018Applicant: BONAC CORPORATIONInventors: Taimu YAMADA, Hidekazu TOYOFUKU
-
Publication number: 20170349902Abstract: The invention provides a single-stranded nucleic acid molecule of (A) or (B) containing a TGF-?1 gene expression inhibitory sequence. The single-stranded nucleic acid molecule (A) consists of region (Xc), linker region (Lx) and region (X) from the 5?-side to the 3?-side, wherein linker region (Lx) has a non-nucleotide structure containing at least one of a pyrrolidine skeleton and a piperidine skeleton, and at least one of region (X) and region (Xc) contains the expression inhibitory sequence.Type: ApplicationFiled: December 15, 2015Publication date: December 7, 2017Applicant: BONAC CORPORATIONInventors: Takahiro MATSUMOTO, Hidekazu TOYOFUKU
-
Publication number: 20170066752Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or of a salt thereof, and a process for producing the same.Type: ApplicationFiled: October 14, 2016Publication date: March 9, 2017Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi YAMASHITA, Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU, Tetsuya YAMAGUCHI, Masahiro SOTA, Shuuji KAWANO, Takayuki NAKAMURA, Ryohei ETO, Takuma IKEBUCHI, Kei MORIYAMA, Nobuaki ITO